Navigation Links
Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
Date:1/15/2014

An article published in the January issue of the International Journal of Radiation Oncology, Biology and Physics reports results of the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of Bevacizumab (Avastin) in addition to cisplatin and pelvic radiation for locally advanced cervical cancer. The group reports that the addition of Bevacizumab to the existing standard of care was safe and showed promising overall results. The 2- and 3- year overall survival rates were 89.8 percent and 80.2 percent, respectively.

"Cervical cancer is a huge problem worldwide, but isn't as big a problem in the United States. So in many ways it tends to become a somewhat overlooked and under-studied disease," says Tracey Schefter, MD, investigator at the University of Colorado Cancer Center, director of the Stereotactic Body Radiation Therapy program at the University of Colorado School of Medicine, and the study's lead author.

Risk factors for cervical cancer include infection with the human papilloma virus (HPV). Screening dramatically reduces both the likelihood of developing cervical cancer and the disease's mortality rate. Combined, these two factors mean that 80 percent of the world's approximately 473,000 yearly cases of cervical cancer occur in the developing world. In the United States, cervical cancer rates have dropped 74 percent over the previous 50 years, but is still diagnosed in approximately 10,000 women per year, with 3,500 deaths due to the disease.

The current phase II clinical trial enrolled 49 eligible patients from 28 institutions in the years 2006-2009. The study previously reported that Bevacizumab was safe and well-tolerated in combination with cisplatin and radiation therapy in this population. Now the group reports on the secondary efficacy endpoints at a median follow-up time of 3.8 years.

Specifically the group evaluated the addition of 10mg/kg bevacizumab every two weeks for 3 cycles during chemoradiation. The overall survival and locoregional control results were favorable in comparison to historical controls of chemoradiation without bevacizumab and warrant further study in a phase III trial.

"Parenthetically, when we were designing this trial, one thing we discussed at length was whether to include a maintenance phase of bevacizumab after chemoradiation. Because of perceived issues with patient compliance at the time, we decided not to add to the overall duration of treatment by adding maintenance Bevacizumab. Based on the recent results of GOG 240 which showed an overall survival benefit when Bevacizumab was added to first line chemotherapy for patients with metastatic disease, a trial addressing the benefit of both concurrent and maintenance bevacizumab for locoregionally advanced cervical cancer will likely need to be done," Schefter says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert  

Related medicine news :

1. ALS patients differ on treatment choices in later phases of disease
2. Reach2HD, a Phase II study in Huntingtons disease, launched
3. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
4. Phase III trial of dapivirine ring begins in Africa: New HIV prevention approach for women
5. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
6. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
7. JDRF announces winners of first phase of Agnes Varis Glucose-Responsive Insulin Challenge
8. Positive results from Phase 1/2 stem cell trial reported
9. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
10. Teva to present new Phase III data for QNASL® Nasal Aerosol at the 2012 ACAAI Meeting
11. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
(Date:5/27/2016)... Columbia, SC (PRWEB) , ... May 27, 2016 , ... ... launched a line of classic American timber frame barn kits, which can be found ... are inspired by historic American barn plans, and they highlight the craftsmanship of ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute ... for a sustainable product to aid in the rehabilitation process has steadily increased. Ekso ... of individuals with hemiplegia due to stroke. , Ekso Bionics has now received clearance ...
(Date:5/27/2016)... ... ... Beleza Medspa has initiated a new program to assist active duty ... that Coolsculpting is being used for for more than just cosmetic purposes. ... prescribed body-fat standard, measured by the circumference-based tape method. The tape-test is used ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team ... and food industries. Aside from its GMP accreditation, Validation Center is also a ... certified products, services and staff. , Validation Center is ISO17025 accredited and only ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, ... defective respirators, according to court documents and SEC filings. A jury has ... Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, California. The ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 2016 According to market research ... and Demand Forecast to 2022 - Industry Insights by ... published by P&S Market Research, the global insulin delivery ... and it is expected to grow at a CAGR ... pump segment is expected to witness the fastest growth ...
(Date:5/25/2016)... May 25, 2016  Granger Diagnostics today announced immediate ... wounds and infections. This test ensures discovery of ... viruses. The test requires only a simple swab of ... David G. Bostwick , MD, Chief Medical ... wound healing: "We are excited to make available, ...
(Date:5/25/2016)... May 25, 2016 MedDay, a biotechnology ... that an oral presentation entitled "High doses of biotin in ... will be given by Professor Ayman Tourbah , Principal ... of the European Academy of Neurology (EAN) in ... disorders 3" will take place on Sunday, 29 May 2016 ...
Breaking Medicine Technology: